<DOC>
	<DOCNO>NCT01247363</DOCNO>
	<brief_summary>Safety study multiple oral dos LY2608204 give patient type 2 diabetes . Study subject receive daily dos LY2608204 total treatment duration 28 day . In study , patient receive increase dos LY2608204 reach high dose tolerate . Continuous glucose monitoring device employ patient monitor hypoglycemia study treatment . Dose titration dose reduction determine individual patient base safety glycemic data .</brief_summary>
	<brief_title>A Study LY2608204 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients diagnose T2DM currently treat diet/lifestyle measure alone combination antidiabetic agent , include insulin Have fast blood glucose ( FBG ) great equal 160 mg/dL , subset patient FBG great equal 190 mg/dL least 2 measurement separate day Have glycated haemoglobin ( HbA1c ) level great equal 8 % less equal 11 % screen If female , childbearing potential due surgical sterilisation ( hysterectomy bilateral oophorectomy tubal ligation ) menopause Are males female least 18 year old ( site outside Singapore ) least 21 year old ( site within Singapore ) 70 year old ( site ) Body mass index ( BMI ) great 18.5 kg/m2 less 40.0 kg/m2 Have clinical laboratory test result within normal range population investigator site , abnormality deem clinically insignificant investigator Have supine systolic blood pressure ( SBP ) great 160 mmHg supine diastolic blood pressure ( DBP ) less 100 mmHg Have venous access sufficient allow blood sample per protocol Are willing able comply requirement continuous glucose monitoring ( CGM ) Are reliable willing make available duration study abide Clinical Research Unit ( CRU ) policy procedure study restriction . This include stay inpatient CRU total duration 31 day Have give write informed consent approve Lilly ethical review board govern site Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device use drug device study drug use study , concurrently enrol type medical research judge scientifically medically compatible study Have significant history past current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine ( diabetes ) , hematological , neurological disorder capable significantly alter absorption , metabolism elimination drug constitute risk take study drug formulation interfere interpretation data Have history seizure disorder A corrected QT interval great 450 msec screen personal history ventricular tachycardia unexplained syncope , abnormality 12lead ECG , opinion investigator , increase risk associate participate study Have family history long QT syndrome family history sudden unexplained death Use medication know prolong QT interval . Have type 1 diabetes mellitus history ketoacidosis type diabetes mellitus type 2 Use known inducer inhibitor CYP3A within 14 day prior first dose study drug intend use study History hypoglycemic event acute mental status alteration precede prodromal symptom recognizable patient Fasting serum triglyceride great 500mg/dl Serum creatinine great 1.3 mg/dL woman , great 1.5 mg/dL men Clinical evidence active diabetic proliferative retinopathy Known clinically significant autonomic neuropathy evidence urinary retention , orthostatic hypotension , diabetic diarrhea gastroparesis Clinically significant coronary event symptom within 6 month prior study entry Clinically significant peripheral vascular disease Have know allergy LY2608204 relate compound Evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibodies/antigen Evidence hepatitis B and/or positive hepatitis B surface antigen ( HBsAg ) Donation loss blood equal exceed 450 mL 3 month first administration study drug Patients average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) ( 1 unit equal 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) patient unwilling stop alcohol consumption 24 hour prior admission completion inpatient study period Patients smoke 10 cigarette tobacco product per day study entry . Patients allow smoke study Unit Have history drug alcohol abuse Intended use overthe counter prescription medication 7 14 day , respectively , prior dosing . If situation arises , inclusion otherwise suitable volunteer may discretion investigator . Use antidiabetic medication [ metformin , sulphonylureas , glinides , thiazolidinediones , acarbose , DPPIV inhibitor , Byetta ( liraglutide ) ] patient type 2 diabetes mellitus acceptable study Have repeat alanine transaminase level great 2.5 time upper limit reference range screening , determined central laboratory Have previously enrol clinical study study LY2608204 . Exclusion Criteria EU/UK/US Site ( ) Evidence hepatitis C and/or positive hepatitis C antibody , screen Use know drug abuse and/or positive finding urinary drug screening , finding consistent medication prescribe patient 's physician overthecounter medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Diabetes glucokinase safety</keyword>
</DOC>